Abstract
REM (rapid eye movement) sleep behavior disorder (RBD) is a well known parasomnia [1]. Its first description in humans dates back to 1985, and its first description in narcoleptic patients to 1992. Although the precise pathophysiology of RBD remains unclear, it is likely, in the case of RBD associated with narcolepsy, that the altered function of hypocretin pathways projecting from the lateral hypothalamus to the ventrolateral part of the periaqueductal grey matter and the lateral pontine tegmentum has a consistent role. The percentage of narcoleptic patients complaining of clinical RBD lies somewhere between 10 and 15% of the narcoleptic population. The age of onset is younger than in the other forms of chronic RBD. Clinical features are the same as in the other forms of chronic RBD, but the frequency of the episodes is less marked. Associated features include other parasomnias, periodic limb movements in sleep (PLMs) and olfactory dysfunction. Polysomnographic tracings are remarkable for elevated submental electromyographic (EMG) tone and/or excessive phasic submental EMG twitching. Data on human leukocyte antigen (HLA) association and on cerebrospinal fluid (CSF) hypocretin/orexin levels are limited. Clinical variants include RBD induced or worsened by pharmacological agents, most of them being used to treat cataplexy, RBD in narcoleptic children and RBD in the context of symptomatic narcolepsy. Several treatments of RBD are available including clonazepam, melatonin and more recently pramipexole. However, in the absence of any pharmacological trials of these drugs on RBD in narcoleptic patients, it is difficult to provide guidance other than to recommend conventional treatments of RBD.
Keywords: Narcolepsy, REM sleep behavior disorder, Pathophysiology, Epidemiology, Clinical variants, Hypocretin/orexin
CNS & Neurological Disorders - Drug Targets
Title: REM Sleep Behavior Disorder and Narcolepsy
Volume: 8 Issue: 4
Author(s): Michel Billiard
Affiliation:
Keywords: Narcolepsy, REM sleep behavior disorder, Pathophysiology, Epidemiology, Clinical variants, Hypocretin/orexin
Abstract: REM (rapid eye movement) sleep behavior disorder (RBD) is a well known parasomnia [1]. Its first description in humans dates back to 1985, and its first description in narcoleptic patients to 1992. Although the precise pathophysiology of RBD remains unclear, it is likely, in the case of RBD associated with narcolepsy, that the altered function of hypocretin pathways projecting from the lateral hypothalamus to the ventrolateral part of the periaqueductal grey matter and the lateral pontine tegmentum has a consistent role. The percentage of narcoleptic patients complaining of clinical RBD lies somewhere between 10 and 15% of the narcoleptic population. The age of onset is younger than in the other forms of chronic RBD. Clinical features are the same as in the other forms of chronic RBD, but the frequency of the episodes is less marked. Associated features include other parasomnias, periodic limb movements in sleep (PLMs) and olfactory dysfunction. Polysomnographic tracings are remarkable for elevated submental electromyographic (EMG) tone and/or excessive phasic submental EMG twitching. Data on human leukocyte antigen (HLA) association and on cerebrospinal fluid (CSF) hypocretin/orexin levels are limited. Clinical variants include RBD induced or worsened by pharmacological agents, most of them being used to treat cataplexy, RBD in narcoleptic children and RBD in the context of symptomatic narcolepsy. Several treatments of RBD are available including clonazepam, melatonin and more recently pramipexole. However, in the absence of any pharmacological trials of these drugs on RBD in narcoleptic patients, it is difficult to provide guidance other than to recommend conventional treatments of RBD.
Export Options
About this article
Cite this article as:
Billiard Michel, REM Sleep Behavior Disorder and Narcolepsy, CNS & Neurological Disorders - Drug Targets 2009; 8 (4) . https://dx.doi.org/10.2174/187152709788921690
DOI https://dx.doi.org/10.2174/187152709788921690 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19
Current Pharmaceutical Design Editorial [Hot Topic: Protein Peptide Informatics and Drug Designing (Guest Editor: Rajani R. Joshi)]
Protein & Peptide Letters Apathy: A Conceptual Review
Current Psychiatry Research and Reviews Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Advances in Reprogramming to Pluripotency
Current Stem Cell Research & Therapy Pharmacology of Nitric Oxide: Molecular Mechanisms and Therapeutic Strategies
Current Pharmaceutical Design Development of Global Consensus of Dengue Virus Envelope Glycoprotein for Epitopes Based Vaccine Design
Current Computer-Aided Drug Design Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Antimicrobial Sulfated Glycans: Structure and Function
Current Topics in Medicinal Chemistry Involvement of Toll-like Receptors in Ischemia-induced Neuronal Damage
Central Nervous System Agents in Medicinal Chemistry Demographic, Clinical and Laboratory Profiles of HIV Infected Patients Admitted into Imam Khomeini Hospital of Tehran, Iran
Infectious Disorders - Drug Targets Biodegradable Polymer Based Particulate Carrier(s) for the Delivery of Proteins and Peptides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry HPV and Therapeutic Vaccines: Where are We in 2010?
Current Cancer Therapy Reviews Harnessing Phage Display for the Discovery of Peptide-Based Drugs and Monoclonal Antibodies
Current Medicinal Chemistry Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials New Opportunities in the Structure-based Design of Anti-Protozoan Agents
Current Topics in Medicinal Chemistry The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals Podocyte Mitosis – A Catastrophe
Current Molecular Medicine